MC2 Therapeutics breakthrough unleashes new skin treatment potential

The Danish biotech firm might have discovered the root cause of several skin diseases, while in vitro modelling shows that a lead candidate has the potential to help the newly discovered problem.

Photo: MC2 Therapeutics / PR

MC2 Therapeutics thinks it might have found ”a novel biological paradigm for treatment of several urea associated skin diseases,” the Danish biotech company announces in a press release.

The discovery also entails the potential root cause for ”several poorly understood skin diseases,” MC2 writes, listing chronic kidney disease associated pruritus and genital lichen sclerosus as two examples. According to the company’s findings, the reason behind such diseases could be ”carbamylation of proteins, peptides and amino acids in the skin, caused by isocyanate.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs